12:00 AM
 | 
Oct 07, 2013
 |  BioCentury  |  Emerging Company Profile

Stem Cell Theranostics: Betting on diversity

Stem Cell Theranostics aims to improve predictive cardio models with iPS cells

Stem Cell Theranostics Inc. aims to reduce clinical attrition rates for drug developers by using human induced pluripotent stem cells to more accurately predict cardiotoxicity and cardiovascular drug efficacy. The company expects the diversity of its disease- and patient-specific cell banks will improve upon traditional preclinical tools, as well as newer tools centered on the use of iPS cells.

The standard preclinical tools for assessing the effects of drugs on the heart are poorly predictive because they rely on cells that lack the full complement of receptors on human cardiomyocytes, or employ animal hearts, whose cardiomyocytes have different electrophysiological properties (see BioCentury, Aug. 5 & SciBX: Science-Business eXchange, Aug. 8).

These problems can be addressed by reprograming human adult somatic cells into induced pluripotent stem (iPS) cells that can then be differentiated into cardiomyocytes.

However, according to Stem...

Read the full 671 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >